Participated · Series A · Jun 2024

MOA Foodtech integrates industrial biotechnology and artificial intelligence to develop high-value food ingredients from agricultural byproducts via a patented fermentation process. It converts substrates such as cereals, bagasse and legumes into competitive, low‑carbon functional ingredients that can be reintroduced into the food system. The company uses its AI platform, Albatros, to accelerate ingredient creation while reducing time and costs. Proceeds from the recent financing are intended to scale operations, expand production and commercialisation, and further develop the Albatros platform for international market launches. Founded in 2021 in Pamplona (Navarra), MOA employs 15 technical staff, 11 of whom are women. The company frames its approach as a circular solution that helps mitigate greenhouse gas emissions, deforestation and biodiversity loss by valorising large volumes of secondary agro‑food flows. MOA Foodtech is an agroalimentaria startup that develops protein ingredients of high nutritional value from agro‑food subproducts. Founded in 2020 and based at the CEIN incubator in Noain (Pamplona‑Iruña), the company is led by scientific director Susana Sánchez, CEO Bosco Emparanza and CFO José María Elorza. The startup aims to address growing demand for alternative proteins and has participated in acceleration programs such as Spain Foodtech and Orizont’s Match Point VI. MOA plans to have its first product on the market in 2022 and to grow its headcount from five employees to fourteen. The company has early commercial ties with Sanygran and Iberfruta, with options for minimum contracts of €25,000.

Participated · Equity · Dec 2023

MainRail develops proprietary software for integrated predictive and corrective maintenance of railway infrastructure, built with support from Inycom as a spin-off of CEIT. Its tool is currently deployed across more than 3,200 kilometers of track. The company has launched a first predictive pandeo (buckling) model based on digital twins and artificial intelligence. MainRail's technology can predict deformation risks from high summer temperatures and is reported to reduce maintenance spending by about 25%. The company announced a new funding round that raised €854,000. The capital will be used to design and execute new technological and functional developments and to boost the company's commercial expansion.

Participated · Equity · Mar 2023

Ojer Pharma is a biopharmaceutical company specialized in dermatology that develops innovative pharmaceutical products and disruptive dosage forms to improve efficacy and reduce toxicity. The company has launched products commercially (including Lavirk in Spain) and secured licensing agreements for Impetine in China and Keramod in Spain and Germany. It has also developed a dermatological veterinary line and continues investing in R&D and new vehiculization technologies. Leadership is headed by CEO and founder Carlos González, who brings 17 years of industry experience, and the team has deep pharmaceutical sector expertise. Financially, the company has completed multiple equity capital increases to support commercialization, regulatory work and product development. Ojer Pharma is a pharmaceutical company spun out of the University of Navarra in 2005 that develops prescription and over‑the‑counter products for dermatology. Its portfolio includes Lipovir®, a bioadhesive hydrogel delivering aciclovir for labial herpes, and Impetine®, a mupirocin bioadhesive lipogel co‑developed with Reig Jofré and in Phase III. The company planned Spanish market launches in 2014 for Previderm® and two Dermatul® products, and expected Lipovir® and Impetine® to reach the market in 2015. The recent financing led by Inveready is intended to finalize key developments and initiate commercial exploitation of high‑value dermatology products. Ojer Pharma is led by CEO Carlos González and has been previously financed by Sodena, Clave Mayor S.G.E.C.R., Ronda Vida F.C.R., Real de Vellón S.A. S.C.R. and other investors.

Participated · Equity · Jul 2020

Eversens designs, develops, manufactures and markets innovative breath analysis solutions that provide clinicians with objective biomarker data. Its first product, evernoa, helps refine asthma diagnosis and therapy selection by measuring airway inflammation and has enabled more than 150,000 tests across 22 countries. Building on this traction, the company has created evernoa mini, a home-use and primary-care device that regularly monitors inflammation to identify patients at risk of asthma attacks. The firm is backed by a global, highly qualified team and leading respiratory KOLs. Eversens plans to expand into additional international markets, including the United States, and is preparing a Series A round to fund this growth. The company positions itself as a leader in breath biomarker analysis aimed at improving the quality of life for millions of respiratory patients worldwide.

Participated · Equity · Feb 2020

ABANZA designs and commercializes soft tissue fixation products, led by its WasherCap™ Fixation System which has FDA clearance for fixation of soft tissue grafts including tendons and ligaments in procedures such as ACL reconstruction. The company completed a preliminary launch with a select group of surgeons and is preparing to introduce the WasherCap™ Mini for additional applications in the knee, hand, wrist, and elbow. ABANZA plans to accelerate its U.S. market entry and expand its field sales team to work with leading orthopedic specialists across key U.S. markets. The company intends to scale staffing, production capacity, and physician education efforts as part of its rollout. ABANZA emphasizes its patented technology to enhance fixation strength regardless of patient bone quality and to minimize graft displacement after surgery. The company is positioning the WasherCap™ line as the lead product in a broader strategy of soft tissue repair solutions. Abanza Tecnomed designs and develops medical devices and surgical instrumentation focused on sports medicine and arthroscopic procedures. Its first product, the WasherCap, is an innovative soft‑tissue fixation system for anterior cruciate ligament (ACL) reconstruction and has obtained CE marking. The company received authorization to commercialize the WasherCap in Europe on 29 January and has also secured ISO 13485 certification for medical‑device manufacturing. Abanza won the Everis Global Award in 2019 and says it will continue R&D in the arthroscopic field while preparing product launch and internationalization. Management frames the market opportunity around the high prevalence of ACL injuries and aims to position the company as a reference in minimally invasive sports‑medicine solutions. Abanza Tecnomed develops medical devices and surgical instruments for sports medicine and traumatology, having created an innovative tibial fixation device for anterior cruciate ligament (ACL) arthroscopic surgery. The new arthroscopic solution aims to address key shortcomings of existing soft‑tissue implant techniques. Clinical trials are planned imminently with Clínica Universidad de Navarra (CUN) and the Arthroscopic Surgery Unit of Hospital Vithas San José de Vitoria, which supported the project during design phases. The company’s stated goals are higher surgeon and patient success rates, fewer reoperations, earlier and less painful rehabilitation, and reduced risk of osteoarthritis (reported to affect 57% of operated ACL patients). Abanza intends to commercialize this tibial fixation device and other arthroscopic systems currently in development. Financially, the company has secured financing commitments to pursue its business plan, including a contribution from UN I+D+i Tech Transfer together with co‑investors.